 Business Wire India Fibrosis regression observed in 50 of patients receiving fazirsiran Median reductions of 94 of Z-AAT accumulation in the liver and mean reduction of 68 in histologic globule burden Treatment emergent adverse events were generally well balanced between fazirsiran and placebo groups Results consistent with AROAAT-2002 open-label study previously ... The post Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-... 